Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study

Asherson, Philip J., Johansson, Lena, Holland, Rachel, Bedding, Megan, Forrester, Andrew ORCID: https://orcid.org/0000-0003-2510-1249, Giannulli, Laura, Ginsberg, Ylva, Howitt, Sheila, Kretzschmar, Imogen, Lawrie, Stephen M., Marsh, Craig, Kelly, Caroline, Mansfield, Megan, McCafferty, Clare, Khan, Khuram, Müller-Sedgwick, Ulrich, Strang, John, Williamson, Grace, Wilson, Lauren, Young, Susan, Landau, Sabine and Thomson, Lindsay D. G. 2023. Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study. British Journal of Psychiatry 222 (1) , pp. 7-17. 10.1192/bjp.2022.77

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (526kB) | Preview

Abstract

Background Research has shown that 20–30% of prisoners meet the diagnostic criteria for attention-deficit hyperactivity disorder (ADHD). Methylphenidate reduces ADHD symptoms, but effects in prisoners are uncertain because of comorbid mental health and substance use disorders. Aims To estimate the efficacy of an osmotic-release oral system methylphenidate (OROS-methylphenidate) in reducing ADHD symptoms in young adult prisoners with ADHD. Method We conducted an 8-week parallel-arm, double-blind, randomised placebo-controlled trial of OROS-methylphenidate versus placebo in male prisoners (aged 16–25 years) meeting the DSM-5 criteria for ADHD. Primary outcome was ADHD symptoms at 8 weeks, using the investigator-rated Connors Adult ADHD Rating Scale (CAARS-O). Thirteen secondary outcomes were measured, including emotional dysregulation, mind wandering, violent attitudes, mental health symptoms, and prison officer and educational staff ratings of behaviour and aggression. Results In the OROS-methylphenidate arm, mean CAARS-O score at 8 weeks was estimated to be reduced by 0.57 points relative to the placebo arm (95% CI −2.41 to 3.56), and non-significant. The responder rate, defined as a 20% reduction in CAARS-O score, was 48.3% for the OROS-methylphenidate arm and 47.9% for the placebo arm. No statistically significant trial arm differences were detected for any of the secondary outcomes. Mean final titrated dose was 53.8 mg in the OROS-methylphenidate arm. Conclusions ADHD symptoms did not respond to OROS-methylphenidate in young adult prisoners. The findings do not support routine treatment with OROS-methylphenidate in this population. Further research is needed to evaluate effects of higher average dosing and adherence to treatment, multi-modal treatments and preventative interventions in the community.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Medicine
Publisher:	Royal College of Psychiatrists
ISSN:	0007-1250
Funders:	Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research partnership (NIHR; grant number 14/23/17).
Date of First Compliant Deposit:	7 June 2022
Date of Acceptance:	27 May 2022
Last Modified:	05 May 2023 15:15
URI:	https://orca.cardiff.ac.uk/id/eprint/150244

Actions (repository staff only)

Edit Item